Sarepta Therapeutics’ Strategic Partnership with Arrowhead Signals Strong Growth ...
Analyst Kostas Biliouris of BMO Capital reiterated a Buy rating on Sarepta Therapeutics (SRPT – Research Report), retaining the price target of ...
Sarepta deal with Arrowhead a ‘prudent move,’ says Leerink
After Sarepta (SRPT) announced a global licensing and collaboration agreement with Arrowhead (ARWR) that adds four clinical-stage siRNA assets ...
Arrowhead制药公司报告转型之年
生物制药公司Arrowhead制药公司 (ARWR)报告了一个转型的财年,其特点是与Sarepta Therapeutics达成重大合作,以及其领先药物候选plazasiran取得进展。尽管2024财年净亏损5.995亿美元,但公司拥有6.81亿美元的现金和投资余额,预计其财务资源可以支持运营到2028年。